Effect of viral respiratory tract infection on outcome of acute otitis media.
We prospectively studied 271 infants and children (2 months to 7 years of age) with acute otitis media (AOM) for viral and bacterial causes, outcome at the end of therapy, and frequency of recurrence within 1 month. Comprehensive virologic methods, including viral antigen detection, cell culture, and serologic studies, were used to diagnose viral infection of the respiratory tract, middle ear, or both. Evidence of viral infection was found in 46% (124/271) of patients with AOM. Sixty-six patients (24%) had virus or viral antigen in the middle ear fluid; 50 of these patients (76%) also had bacteria in middle ear fluid, and 16 (24%) had virus alone. More patients with AOM and combined bacterial and viral infection (51%) had persistent otitis (3 to 12 days after institution of antibiotic treatment), compared with those with only bacterial otitis (35%; p = 0.05) or patients with only viral infection (19%; p less than 0.01). Of patients with only viral infection, 4 of 10 with virus in middle ear fluid had persistent otitis, compared with none of 11 patients who had virus only in nasal wash specimens or whose viral infection was diagnosed only by serologic studies. Our data suggest that viruses interact with bacteria and that concurrent viral infection can significantly worsen the clinical course of bacterial AOM. The presence of virus in middle ear fluid may contribute to the pathogenesis and outcome of bacterial AOM. The mechanism of these interactions deserve further investigation.
Chonmaitree
T
T
Department of Pediatrics, University of Texas Medical Branch, Galveston 77550.
Owen
M J
MJ
Patel
J A
JA
Hedgpeth
D
D
Horlick
D
D
Howie
V M
VM
D000658:Amoxicillin / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D001424:Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology; D015296:Ceftizoxime / Q000031:analogs & derivatives / Q000627:therapeutic use; D017291:Clarithromycin; D002969:Clavulanic Acids / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004917:Erythromycin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010033:Otitis Media / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D012141:Respiratory Tract Infections / Q000453:epidemiology*; D016896:Treatment Outcome; D014777:Virus Diseases / Q000453:epidemiology*; D000097623:Cefpodoxime
D000658:Amoxicillin; D019980:Amoxicillin-Potassium Clavulanate Combination; D015296:Ceftizoxime; D017291:Clarithromycin; D002969:Clavulanic Acids; D004917:Erythromycin; D000097623:Cefpodoxime